Growing interest in cosmetic procedures is expected to drive botox market expansion in the near future at a CAGR of 10.50% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published on the “Global Botox market”.

The botox market is estimated to register a CAGR of 10.50% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global botox market - AbbVie Inc. (U.S.), Lanzhou Institute of Biological Products Co., Ltd. (China), Ipsen Pharma (France), Merz Pharma (Germany), Medytox (South Korea), GALDERMA (Switzerland), HUGEL, Inc. (South Korea), Evolus, Inc. (U.S.), Revance Therapeutics, Inc. (U.S.), and Supernus Pharmaceuticals, Inc. (U.S.).

Market Highlights

The global botox market is accounted to register a CAGR of 10.50% during the forecast period and is estimated to reach USD 11.052 billion by 2032.

Over the projection period, there is expected to be a rise in the global demand for botulinum toxin due to several factors, including an aging population, an increase in the number of procedures involving the toxin, and a growth in people's self-awareness regarding their looks. Moreover, the growth of the botulinum toxin market is also fueled by players investing more in R&D, having strong pipeline candidates, spending more on building healthcare infrastructure, making botulinum injections more affordable, and changing reimbursement policies to include botulinum injections.

Segment Analysis

The global botox market has been segmented into application, type, and end-user.

On the basis of application, the market is segmented into Therapeutics (Chronic Migraine, Spasticity, Overactive Bladder, Cervical Dystonia, Blepharospasm, Others) and Aesthetics. The aesthetics segment was attributed to holding the largest market share in 2022. Botulinum toxin demand is expected to be driven by rising awareness of the use of these products for aesthetic purposes as well as rising desire for minimally invasive procedures.

Based on type, the global botox market has been segmented into Botulinum Toxin Type A and Botulinum Toxin Type B. The botulinum toxin type A segment was expected to hold the largest market share in 2022. Increased demand for facial wrinkle reduction and an increase in the majority of chronic conditions. Because of its great endurance and efficacy, as well as the growing emphasis of manufacturers on improving production capacity, people prefer to use Botulinum Toxin A.

Based on end-user, the global botox market has been segmented into Specialty & Dermatology Clinics, Hospitals & Clinics, and Others. The specialty & dermatology clinics segment was expected to hold the largest market share in 2022. The majority of skin-related conditions are becoming more prevalent, research into sophisticated dermatological products and remedies is progressing, concerns about aesthetic appearance are growing, and the number of cosmetic surgical procedures is expanding.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Bioinformatics Market Research Report

Regional Analysis

The global botox market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe botox market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The botox market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World botox market comprises of Middle East, Africa, and Latin America.

The largest market share for botox was maintained by the North American regional sector The elements that support the region's growth are the rising number of product launches, the presence of large corporations, and the region's residents' growing adoption of these practices. For instance, over 2,520,000 botulinum toxin operations were carried out in the United States in 2021, according to the International Society of Aesthetic Plastic Surgery.

Moreover, the Europe market has been persistently growing over the forecast period due to the fact that people in important European nations are beginning to favor these operations increasingly. Additionally, a major contributing cause to the expansion of the European region is the growing amount of money spent on R&D projects to introduce new products.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period. The increasing incidence and prevalence of chronic conditions as well as the growing number of people who are conscious about their physical appearance are the reasons behind the growing popularity of these operations in Asia. The majority of these treatments are carried out in dermatology and specialized clinics, which is fueling the expansion of this market.

Furthermore, the rest of the world's botox market is divided into the Middle East, Africa, and Latin America. The region will develop as a result of the rising number of procedures in important Latin American nations like Brazil. The region's increasing trends in using these items for aesthetic operations and people's increased awareness both support the market's expansion. Additionally, it is anticipated that the number of these treatments will rise across the Middle East and Africa. The global market has grown as a result of rising health and beauty standards and rising per capita healthcare spending.

Key Findings of the Study

• The global botox market is expected to reach USD 11.052 billion by 2032, at a CAGR of 10.50% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market. The rising popularity of these procedures in Asia Pacific can be attributed to the rising incidence of chronic diseases as well as the rising number of individuals who are self-conscious about their physical appearance.


• Based on application, the aesthetics segment was attributed to holding the largest market in 2022, with an approximate market share of 60%.


• AbbVie Inc. (U.S.), Lanzhou Institute of Biological Products Co., Ltd. (China), Ipsen Pharma (France), Merz Pharma (Germany), Medytox (South Korea), GALDERMA (Switzerland), HUGEL, Inc. (South Korea), Evolus, Inc. (U.S.), Revance Therapeutics, Inc. (U.S.), and Supernus Pharmaceuticals, Inc. (U.S.).